WASHINGTON, April 20, 2015 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Phase 1 clinical data from the company’s joint development program with Roche and the SMA Foundation in spinal muscular atrophy (SMA) will be presented at the 2015 American Academy of

Share on LinkedInShare on FacebookShare on Google+Pin on PinterestEmail this to someone